Pharmacokinetics

Phase I Study Explores MDXH210/Interferon (gamma) Combination in Cancer Patients

Published in Cancer Weekly, April 4th, 2000

Researchers from the United States explored the pharmacokinetic-pharmacodynamic (PK-PD) relationships of the bispecific antibody MDXH210 when it was combined with interferon gamma (IFN-(gamma)) in Her-2-positive cancer patients.

"MDXH210 is a Fab'xFab' bispecific antibody (BsAb) constructed chemically by crosslinking Fab' MAb 520C9 (anti-Her-2/neu) and Fab' MAb22 (anti-CD64)," explained L.D. Lewis and colleagues from the Dartmouth-Hitchcock Medical Center, New Hampshire, and Medarex, Inc., New Jersey, USA. "CD64 (FcgammaRI) is the high affinity membrane receptor for IgG," they added.

Lewis et al. presented data from their study at the annual meeting...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-04-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry